SEC Form 4 · accession 0001209191-17-051449
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey S Glenn
Director
Period of report
Sep 1, 2017
Accepted (ET)
Sep 5, 2017 · 6:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2017 | P | 15,000 | $9.53 | A | 31,355 | D | |
| Common Stock | holding | — | — | — | 460 | I | By son | |
| Common StockF1 | holding | — | — | — | 151,064 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares are held by Eiger Group International, Inc. ("EGI"). The Reporting Person is the Chief Executive Officer of EGI and has sole power to vote and sole power to dispose of shares directly owned by EGI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.